Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison. (31st August 2018)

• Record Type: Journal Article
• Authors: Ishak, K Jack; Rael, Michael; Hicks, Meagen; Mittal, Sangeeta; Eatock, Martin; Valle, Juan W
• Is Part Of: Journal of comparative effectiveness research. Volume 7:Number 10(2018)
• Page Start: 947
• Page End: 958
• Publication Date: 2018-08-31
• Subjects: comparative effectiveness -- everolimus -- MAIC -- matching-adjusted indirect comparison -- sunitinib; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer-2018-0020
• Languages: English
• ISSNs: 2042-6305

Abstract

Aim: A matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111).Methods: The MAIC matched on all baseline characteristics available from both studies. An anchored MAIC was performed for progression-free survival (PFS); an unanchored analysis was deemed more appropriate for OS due to crossover in both trials. A hazard ratio for sunitinib versus everolimus was derived from adjusted (weighted) sunitinib effects compared with the observed results for everolimus.Results: The adjusted hazard ratio for sunitinib versus everolimus was 0.85 (0.39–1.89) for PFS and 0.82 (0.53–1.27) for OS.Conclusion: Findings indicate comparable PFS and OS with sunitinib and everolimus.